FSD Pharma: Developing Novel Solutions for Brain & Inflammatory Disorders
FSD Pharma (CSE: HUGE, NASDAQ: HUGE) is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma, with only 38.4 million shares issued/outstanding, is a biotechnology company with three drug candidates in different stages of development.
FSD BioSciences, Inc. (“FSD BioSciences”), a wholly-owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly-owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
For more information on FSD Pharma Inc. (CSE: HUGE, NASDAQ: HUGE) please click the request investor info button.
Latest Articles
Hot Companies
You might also like
.jpg)
ONGold Resources: Unlocking Canada’s Hidden Gold Potential
ONGold Resources is redefining mineral exploration with a fresh approach to unlocking gold in Canada’s most prolific mining belt. Their data-driven, modern exploration strategy aims to turn untapped geology into next-generation discovery.
